Lenzing's €300 Million Rights Issue: Inside Allocations, Berenberg's Downgrade and the Looming Dilution Test

Lenzing allocates subscription rights to Skilich and Oberbank as its EUR 300 million cash capital increase runs through October 2026.

Lenzing has begun allocating subscription rights to two prominent recipients, board member Christian Skilich and Oberbank AG, with the underlying transactions dated Tuesday. The disclosures, released Thursday, mark procedural milestones inside a capital raise that is still running — not its conclusion.

At the heart of the exercise sits a cash capital increase targeting gross proceeds of roughly EUR 300 million. New shares are offered at EUR 8.65 apiece on a 10:9 subscription ratio. Management intends to channel the money into strengthening the balance sheet while financing its "Grow Nonwovens, Reset Textiles" strategy. For existing holders, that packages a financing question and a vote of confidence into a single decision.

Two Clocks Are Ticking

The near-term calendar is what forces the issue. Trading in the subscription rights is scheduled to run through October 14, 2026, while the subscription period itself opened Tuesday and closes on October 20, 2026. Lenzing also plans an international private placement of any unsubscribed new shares on that closing date, moving the process from rights holders' choices to the placement of leftover stock. Book entry, delivery and trading of the new shares are expected to commence around October 23, 2026, conditional on the capital increase being registered in the commercial register.

Investors therefore face two distinct timelines: a time-bound call on their rights, and a far longer judgment on the company itself. Backing the financing is not the same as endorsing the business trajectory.

Berenberg's Downgrade Sharpens the Focus

The operational test is where scrutiny belongs. A warning arrived roughly a week ago from Berenberg, which cut Lenzing to Hold from Buy and slashed its price target to EUR 17.00 from EUR 29.50. Among the reasons cited: higher cotton and viscose prices had failed to feed through to earnings as anticipated.

That assessment draws a line between market conditions and corporate delivery. A convincing bull case would require Lenzing to demonstrate that favorable pricing actually lands in the numbers. A sturdier financial base helps — but it cannot substitute for operational progress. Keeping those two ideas apart should shape how the capital measure is judged.

Guarantees Underpin the Financing, Not the Earnings

Supporting the optimistic scenario is the backstop itself. According to the company, the syndicate banks fully guarantee the transaction, and the B&C Group, Suzano S.A. and Oberbank AG have committed to exercising their subscription rights. Those pledges shore up the financing plan without pre-empting its full execution.

Suzano's commitment, however, comes with an asterisk. Handelsblatt reports that the Brazilian pulp producer does not intend to participate in full. That stance does not equate to the financing failing, but it does leave the question of how investors read the uneven appetite among major holders.

Should the plan unfold as intended, Lenzing could pair a stronger capital structure with its strategic repositioning. The guarantee improves the starting position of that scenario. It guarantees neither higher returns nor a re-rating of the stock.

Dilution Keeps the Pressure On

The counterargument rests on the sheer size of the issuance. Lenzing plans 34,756,362 new shares, a substantial expansion of the share count. N-tv attributed selling pressure to the capital increase and the associated dilution.

A negative path would be a successful financing without sufficient operational improvement — a stronger balance sheet, but the weak pass-through of favorable prices that Berenberg flagged left unresolved. The subscription price of EUR 8.65 is itself no proof of an attractive valuation; it is one of the terms of the measure. Long-term appeal depends on what Lenzing does with the proceeds. Blur the two, and the financing's evidentiary value for the business gets overstated.

What Would Vindicate the Raise

As long as the guarantees and exercise commitments carry the plan, execution on that basis remains plausible. If the operational payoff lags expectations, though, a completed capital raise would not solve the core valuation problem. The investment case hinges not only on closing the transaction but on the strategy proving itself economically.

The optimistic reading demands more than a rights period running to schedule. It requires that financial support translate into demonstrable progress in the business. Until Lenzing shows tangible advances in the announced realignment, the strengthened capital base remains a prerequisite for the intended change — not evidence that it has already arrived.